Special Feature "Pharmaceutical Cooperative Industry Vision 2035
Drug Discovery Innovation for Japan and the World
Amidst the drastically changing environment surrounding the pharmaceutical industry, the Pharmaceutical Manufacturers Association of Japan (PMAJ) has newly formulated its "Industrial Vision 2035. The vision consists of the three pillars of Innovation, Access, and Trust, and we would like to introduce our vision for the future and our efforts to realize it.
From JPMA
Interview with Asuka Miyabashira, New President
The future of the pharmaceutical industry as envisioned by Mr. Miyabashira, who assumed the position of President of the Pharmaceutical Association of Japan in May 2025. He spoke about his determination to transform Japan into an attractive market by promoting co-creation, viewing the three crises of declining drug discovery capabilities, stable supply problems, and tight healthcare finances as "opportunities".
My Committee
vol.3 Code Compliance Promotion Committee
The Code Compliance Promotion Committee, which plays a key role in enhancing the credibility of the pharmaceutical industry, is at the forefront of activities to tackle five key issues and share high ethical standards for the benefit of patients throughout the industry, and the passion of the committee members.
The Pharmaceutical Industry from a Factual Perspective
Characteristics of New Drugs Approved in Japan
New drugs approved in Japan before their market launch are often regarded as "country drugs" that are not accepted overseas. A comprehensive survey conducted by the Pharmaceutical and Industrial Policy Research Institute (PIIPRI) reveals the reality and usefulness of these drugs. The survey will reconsider the view of "country drugs.
Key words to keep in mind
The Impact of the New U.S. Administration on the Pharmaceutical Industry
The Japanese pharmaceutical industry, which has been promoting globalization in recent years, faces a new challenge: heightened geopolitical risks under the new U.S. administration. Experts will provide urgent commentary on what risks are of concern in drug development and manufacturing and how companies should respond.
Topics
Introducing various topics within the association
We will bring you the latest developments, including the press conference by new President Miyabashira, the 14th APAC meeting, and the 2025 revision of the Pharmaceutical Cooperative Code of Practice.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire